Physician profile
Attique Samdani
NPI 1285697276
$103,731.90
in general payments reported to CMS, 2019-2025
67 companies · $2,914 in 2025
The $2,914 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $22K · 2021: $14K · 2022: $15K · 2023: $9,841 · 2024: $7,801 · 2025: $2,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $5,228 · Travel and Lodging: $442 · Honoraria: $200 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,502.50 |
| Food and Beverage | $5,227.97 |
| Travel and Lodging | $442.23 |
| Honoraria | $200.00 |
| Education | $183.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $14,472.89 | 2019-2024 | Jakafi, Pemazyre, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $13,850.14 | 2019-2024 | Imfinzi, Calquence, Tagrisso |
| Seagen INC. | $13,406.65 | 2019-2023 | Adcetris, Padcev |
| Verastem, INC. | $7,613.99 | 2019-2020 | |
| Cti Biopharma Corp. | $5,808.26 | 2022-2023 | Vonjo |
| Genzyme Corporation | $5,617.25 | 2019-2024 | |
| Rigel Pharmaceuticals, INC. | $3,884.03 | 2019-2024 | Tavalisse, Rezlidhia |
| Takeda Pharmaceuticals U.S.A., INC. | $3,295.79 | 2019-2024 | Alunbrig, Ninlaro, Iclusig |
| E.R. Squibb & Sons, L.L.C. | $3,291.21 | 2019-2025 | Opdivo, Opdualag |
| Beigene USA, INC. | $3,089.82 | 2020-2025 | Brukinsa |
| Blueprint Medicines Corporation | $2,662.00 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $2,498.55 | 2022 | |
| Pfizer INC. | $2,215.16 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $2,156.72 | 2020 | |
| Kite Pharma, INC. | $2,033.44 | 2019 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $1,796.04 | 2021-2024 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $1,703.68 | 2019-2024 | Darzalex, Imbruvica, Rybrevant |
| Exelixis INC. | $1,470.00 | 2021 | |
| Athenex Pharmaceutical Division, LLC | $1,400.00 | 2020 | |
| Aveo Pharmaceuticals, INC. | $1,378.83 | 2023-2024 | Fotivda |
| Tesaro, INC. | $1,273.70 | 2019 | |
| Taiho Oncology, INC. | $1,131.03 | 2020-2023 | |
| Daiichi Sankyo INC. | $941.18 | 2022-2025 | Vanflyta, Enhertu, Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $934.91 | 2019-2024 | |
| Astellas Pharma US INC | $700.80 | 2021-2024 | Xospata, Xtandi, Padcev |
| Emd Serono, INC. | $543.88 | 2021-2024 | Bavencio |
| Novartis Pharmaceuticals Corporation | $534.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $353.22 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Alexion Pharmaceuticals, INC. | $336.54 | 2022-2025 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $285.09 | 2024 | Libtayo |
| Sobi, INC | $277.95 | 2022-2024 | |
| Glaxosmithkline, LLC. | $257.01 | 2021-2024 | Ojjaara |
| Janssen Pharmaceuticals, INC | $203.33 | 2023-2024 | Xarelto, Rybrevant |
| Novocure Gmbh | $200.00 | 2022 | |
| Genentech USA, INC. | $195.25 | 2022-2025 | Rozlytrek, Alecensa, Gavreto |
| Ipsen Biopharmaceuticals, INC | $193.54 | 2022-2025 | Onivyde, Somatuline Depot, Tazverik |
| Gilead Sciences, INC. | $168.83 | 2021-2025 | Trodelvy |
| Eisai INC. | $163.98 | 2023-2025 | |
| Pharming Healthcare, INC. | $124.74 | 2023 | Joenja |
| Abbvie INC. | $102.53 | 2022-2025 | Venclexta |
| Cardinal Health 110 LLC | $100.00 | 2020 | |
| Array Biopharma INC | $87.72 | 2023-2025 | Braftovi, Mektovi, Tukysa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.89 | 2024 | Jardiance |
| Lilly USA, LLC | $79.24 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Mirati Therapeutics, INC. | $77.58 | 2023-2024 | Krazati |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Medtronic, INC. | $66.77 | 2023 | Closurefast |
| Pharmacyclics LLC, An Abbvie Company | $53.19 | 2022-2023 | Imbruvica |
| Servier Pharmaceuticals LLC | $51.96 | 2022-2024 | |
| Acrotech Biopharma INC. | $49.50 | 2023-2024 | Beleodaq |
| Amgen INC. | $48.49 | 2023 | Lumakras |
| G1 Therapeutics, INC. | $41.31 | 2022-2023 | Cosela |
| Adaptive Biotechnologies Corporation | $37.86 | 2022-2023 | Clonoseq |
| Azurity Pharmaceuticals, INC. | $35.71 | 2024 | Vivimusta |
| Adc Therapeutics America, INC. | $34.26 | 2023-2024 | |
| Puma Biotechnology, INC. | $31.50 | 2023 | |
| Apellis Pharmaceuticals, INC. | $31.06 | 2024 | Empaveli |
| Blue Earth Diagnostics | $28.10 | 2023 | |
| Tersera Therapeutics LLC | $24.53 | 2024 | Zoladex |
| Deciphera Pharmaceuticals INC. | $19.72 | 2024 | Tgct, Qinlock |
| Legend Biotech USA INC. | $19.11 | 2025 | Carvykti |
| Pharmacosmos Therapeutics INC. | $17.59 | 2025 | Monoferric |
| Coherus Oncology, INC. | $17.30 | 2023 | |
| Progenics Pharmaceuticals, INC. | $16.86 | 2024 | |
| Springworks Therapeutics, INC. | $16.16 | 2024 | Ogsiveo |
| Genmab U.S., INC. | $15.00 | 2023 | Epkinly |
| Cumberland Pharmaceuticals, INC. | $13.40 | 2024 | Sancuso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Attique Samdani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.